Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men
Anja Blumeyer,
Antonella Tosti,
Andrew Messenger,
Pascal Reygagne,
Veronique del Marmol,
Phyllis I. Spuls,
Myrto Trakatelli,
Andreas Finner, Franklin Kiesewetter,
Ralph Trüeb,
Berthold Rzany,
Ulrike Blume-Peytavi,
Anja Blumeyer
Department of Dermatology and Allergy, Clinical Research Center for Hair and Skin Science, Charité– Universitätsmedizin, Berlin, Germany
Search for more papers by this authorAntonella Tosti
Department of Dermatology, University of Bolognia, Italy and Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, FL, USA
Search for more papers by this authorAndrew Messenger
Department of Dermatology, University of Sheffield, UK
Search for more papers by this authorPascal Reygagne
Centre Sabouraud, Hôpital St. Louis, Paris, France
Search for more papers by this authorVeronique del Marmol
Private Practice and Dermatology Department, Hôpital Erasme, Université Libre de Bruxelles, Bruxelles, Belgium
Search for more papers by this authorPhyllis I. Spuls
Department of Dermatology, Academic Medical Center, Amsterdam, The Netherlands
Search for more papers by this authorMyrto Trakatelli
Department of Dermatology and Venerology, Papageorgiou Hospital, Aristotle University, Thessaloniki, Greece
Search for more papers by this authorFranklin Kiesewetter
Department of Dermatology, Venerology and Allergology, University of Erlangen, Germany
Search for more papers by this authorRalph Trüeb
Department of Dermatology, University Hospital Zürich and Private Practice, Wallisellen, Switzerland
Search for more papers by this authorBerthold Rzany
Department of Dermatology and Allergy, Division of Evidence based Medicine, Charité– Universitätsmedizin, Berlin, Germany
Search for more papers by this authorUlrike Blume-Peytavi
Department of Dermatology and Allergy, Clinical Research Center for Hair and Skin Science, Charité– Universitätsmedizin, Berlin, Germany
Search for more papers by this authorAnja Blumeyer,
Antonella Tosti,
Andrew Messenger,
Pascal Reygagne,
Veronique del Marmol,
Phyllis I. Spuls,
Myrto Trakatelli,
Andreas Finner, Franklin Kiesewetter,
Ralph Trüeb,
Berthold Rzany,
Ulrike Blume-Peytavi,
Anja Blumeyer
Department of Dermatology and Allergy, Clinical Research Center for Hair and Skin Science, Charité– Universitätsmedizin, Berlin, Germany
Search for more papers by this authorAntonella Tosti
Department of Dermatology, University of Bolognia, Italy and Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, FL, USA
Search for more papers by this authorAndrew Messenger
Department of Dermatology, University of Sheffield, UK
Search for more papers by this authorPascal Reygagne
Centre Sabouraud, Hôpital St. Louis, Paris, France
Search for more papers by this authorVeronique del Marmol
Private Practice and Dermatology Department, Hôpital Erasme, Université Libre de Bruxelles, Bruxelles, Belgium
Search for more papers by this authorPhyllis I. Spuls
Department of Dermatology, Academic Medical Center, Amsterdam, The Netherlands
Search for more papers by this authorMyrto Trakatelli
Department of Dermatology and Venerology, Papageorgiou Hospital, Aristotle University, Thessaloniki, Greece
Search for more papers by this authorFranklin Kiesewetter
Department of Dermatology, Venerology and Allergology, University of Erlangen, Germany
Search for more papers by this authorRalph Trüeb
Department of Dermatology, University Hospital Zürich and Private Practice, Wallisellen, Switzerland
Search for more papers by this authorBerthold Rzany
Department of Dermatology and Allergy, Division of Evidence based Medicine, Charité– Universitätsmedizin, Berlin, Germany
Search for more papers by this authorUlrike Blume-Peytavi
Department of Dermatology and Allergy, Clinical Research Center for Hair and Skin Science, Charité– Universitätsmedizin, Berlin, Germany
Search for more papers by this authorProf. Dr. med. Ulrike Blume-Peytavi Department of Dermatology and Allergy Clinical Research Center for Hair and Skin Science Charité– Universitätsmedizin Berlin Charitéplatz 1 D-10117 Berlin, Germany Phone: +49-30-45051-8229 Fax: +49-30-45051-8952 E-Mail: [email protected]
Summary
Androgenetic alopecia is the most common hair loss disorder, affecting both men and women. Initial signs of androgenetic alopecia usually develop during teenage years leading to progressive hair loss with a pattern distribution. Moreover, its frequency increases with age and affects up to 80 % Caucasian men and 42 % of women.
Patients diagnosed with androgenetic alopecia may undergo significant impairment of quality of life. Despite the high prevalence and the variety of therapeutic options available, there have been no national or international evidence-based guidelines for the treatment of androgenetic alopecia in men and women so far. Therefore, the European Dermatology Forum (EDF) initiated a project to develop an evidence-based S3 guideline for the treatment of andro-genetic alopecia. Based on a systematic literature research the efficacy of the currently available therapeutic options was assessed and therapeutic recommendations were passed in a consensus conference.
The purpose of the guideline is to provide dermatologists as well as general practitioners with an evidence-based tool for choosing an efficacious and safe therapy for patients with androgenetic alopecia.
References
- 1 Alfonso M, Richter Appelt H, Tosti A, Viera MS, Garcia M. The psycho-social impact of hair loss among men: A multinational European study. Curr Med Res Opin 2005; 21(11): 1829–36.
- 2 Cash T F, Price VH, Savin RC. Psychological effects of androgenetic alopecia on women: comparisons with balding men and with female control subjects. J Am Acad Dermatol 1993; 29(4): 568–75.
- 3 Blume-Peytavi U, Blumeyer A, Tosti A, Finner A, Marmol V, Trakatelli M, Reygagne P, Messenger A; European Consensus Group. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. Br J Dermatol 2011; 164(1): 5–15.
- 4
Messenger A.
Androgenetic alopecia in men. In: U Blume-Peytavi,
A Tosti,
DA Whiting,
R Trüeb: Hair growth and disorders.
Berlin Heidelberg
: Springer Verlag, 2008: 159–70.
10.1007/978-3-540-46911-7_9 Google Scholar
- 5 Kim BJ, Kim JY, Eun HC, Kwon OS, Kim MN, Ro BI. Androgenetic alopecia in adolescents: a report of 43 cases. J Dermatol 2006; 33(10): 696–9.
- 6 Price VH. Androgenetic alopecia in adolescents. Cutis 2003; 71(2): 115–21.
- 7 Smith MA, Wells RS. Male-type alopecia, alopecia areata, and normal hair in women; family histories. Arch Dermatol 1964; 89: 95–8.
- 8 Hillmer AM, Brockschmidt FF, Hanneken S, Eigelshoven S, Steffens M, Flaquer A, Herms S, Becker T, Kortüm AK, Nyholt DR, Zhao ZZ, Montgomery GW, Martin NG, Mühleisen TW, Alblas MA, Moebus S, Jöckel KH, Bröcker-Preuss M, Erbel R, Reinartz R, Betz RC, Cichon S, Propping P, Baur M P, Wienker T F, Kruse R, Nöthen MM. Susceptibility variants for male-pattern baldness on chromosome 20p11. Nat Genet 2008; 40(11): 1279–81.
- 9 Richards JB, Yuan X, Geller F, Waterworth D, Bataille V, Glass D, Song K, Waeber G, Vollenweider P, Aben KK, Kiemeney LA, Walters B, Soranzo N, Thorsteinsdottir U, Kong A, Rafnar T, Deloukas P, Sulem P, Stefansson H, Stefansson K, Spec-tor TD, Mooser V. Male-pattern baldness susceptibility locus at 20p11. Nat Genet 2008; 40(11): 1282–4.
- 10 Birch M P, Messenger J F, Messenger AG. Hair density, hair diameter and the prevalence of female pattern hair loss. Br J Dermatol 2001; 144(2): 297–304.
- 11 Norwood OT. Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg 2001; 27(1): 53–4.
- 12 Alanis A, Barbara F, Meurehg C, De Oca FL, Ramirez L. Double-blind comparison of 2 % topical minoxidil and placebo in early male pattern baldness. Curr Ther Res Clin Exp 1991; 49(5): 723–30.
- 13 Anderson CD, Hansted B, Abdallah MA, Oumeish OY, Rushaidat Q, Moerk C, Juhlin L; Scandinavian and Middle-Eastern topical minoxidil study group. Topical minoxidil in androgenetic alopecia. Scandinavian and Middle East experience. Int J Dermatol 1988; 27(6 Suppl.): 447–51.
- 14 Arca E, Acikgoz G, Tastan HB, Köse O, Kurumlu Z. An open, randomized, comparative study of oral finaste-ride and 5 % topical minoxidil in male androgenetic alopecia. Dermatology 2004; 209(2): 117–25.
- 15 Bazzano GS, Terezakis N, Galen W. Topical tretinoin for hair growth promotion. J Am Acad Dermatol 1986; 15(4 Pt 2): 880–83.
- 16 Berger RS, Fu JL, Smiles KA, Turner CB, Schnell BM, Werchowski KM, Lammers KM. The effects of minoxidil, 1 % pyrithione zinc and a combination of both on hair density: a randomized controlled trial. Br J Dermatol 2003; 149(2): 354–62.
- 17 Califano A, Virgili A, Caputo R, Cavalieri R, Celleno L, Finzi A, Boneschi V, Guarneri B, Meneghini CL, D’Ovidio R, Guarrera M, Sapuppo A, Di Prima T, Goitre M, Roncarolo G. 2 % Minoxidil topical solution in the treatment of alopecia androgenetica. A controlled clinical study. G Ital Dermatol Venereol 1991; 126(3): 5–10.
- 18
Civatte J,
Laux B,
Simpson NB,
Vickers CF.
2 % topical minoxidil solution in male-pattern baldness: preliminary European results.
Dermatolo-gica
1987; 175 (2 Suppl.): 42–9.
10.1159/000248902 Google Scholar
- 19 Civatte J, Degreef H, Dockx P, Kint A, Lachapelle JM, Amblard P, Bonerandi JJ, Kalis B, Schnitzler L, Haneke E, Laux B, Moragas JM, del Pino J, Quintanilla E, Robledo A, Simpson NB, Vickers C; European topical minoxidil study group. Topical 2 % minoxidil solution in male pattern alopecia: The initial european experience. Int J Dermatol 1988; 27(6 SUPPL.): 424–9.
- 20 Connors TJ, Cooke DE, De-Launey WE, Downie M, Knudsen RG, Shumack S, Eggleston AS. Australian trial of topical minoxidil and placebo in early male pattern baldness. Australas J Dermatol 1990; 31(1): 17–25.
- 21 De-Villez RL. Androgenetic alopecia treated with topical minoxidil. J Am Acad Dermatol 1987; 16(3 Pt 2): 669–72.
- 22 Dutrée-Meulenberg ROGM, Nieboer C, Koedijk FHJ, Stolz E. Treatment of male pattern alopecia using topical minoxidil in The Netherlands. Int J Dermatol 1988; 27(6 SUPPL.): 435–40.
- 23 Karam P. Topical minoxidil therapy for androgenic alopecia in the Middle East. The Middle-Eastern Topical Minoxidil Study Group. Int J Derma-tol 1993; 32(10): 736–66.
- 24 Katz HI, Hien NT, Prawer SE, Goldman SJ. Long-term efficacy of topical minoxidil in male pattern baldness. J Am Acad Dermatol 1987; 16(3 Pt 2): 711–8.
- 25 Koperski JA, Orenberg EK, Wilkinson DI. Topical minoxidil therapy for androgenetic alopecia. A 30-month study. Arch Dermatol 1987; 123(11): 1483–7.
- 26 Kreindler TG. Topical minoxidil in early androgenetic alopecia. J Am Acad Dermatol 1987; 16(3 Pt 2): 718–24.
- 27 Lopez-Bran E, Robledo A, Aspiolea F, Moragas JM, Yu A, Quintanilla E, Sambrico F, del Pino J. Multicenter comparative study of the efficacy of topical 2 % minoxidil (Regaine) versus placebo in the treatment of male baldness. Adv Ther 1990; 7(3): 159–68.
- 28 Montagnani A, Bardazzi F. Open not controlled clinical study on 2 % topical minoxidil solution in the treatment of patients with androgene-tic alopecia. Dermatol Clin 1990; 10(1–4): 47–9.
- 29 Olsen EA, Weiner MS, DeLong ER, Pinnell SR. Topical minoxidil in early male pattern baldness. J Am Acad Dermatol 1985; 13(2 Pt 1): 185–92.
- 30 Olsen EA, DeLong ER, Weiner MS. Dose-response study of topical mino-xidil in male pattern baldness. J Am Acad Dermatol 1986; 15(1): 30–7.
- 31 Olsen EA, DeLong ER, Weiner MS. Long-term follow-up of men with male pattern baldness treated with topical minoxidil. J Am Acad Dermatol 1987; 16(3 Pt 2): 688–95.
- 32 Olsen EA, Weiner MS, Amara IA, DeLong ER. Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil. J Am Acad Dermatol 1990; 22(4): 470–2.
- 33 Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, Trancik RJ. A randomized clinical trial of 5 % topical minoxidil versus 2 % topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2002; 47(3): 377–85.
- 34 Olsen EA, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R, Zhang P, Kohut B. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5 % minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2007; 57(5): 767–74.
- 35 Petzoldt D, Borelli S, Braun-Falco O, Holzmann H, Laux B, Metz J, Petzoldt D, Wolff HH. The German double-blind placebo-controlled evaluation of topical minoxidil solution in the treatment of early male pattern baldness. Int J Dermatol 1988; 27(6 Suppl.): 430–4.
- 36 Piepkorn MW, Weidner M. Comparable efficacy of 2 % minoxidil gel and solution formulations in the treatment of male pattern alopecia. J Am Acad Dermatol 1988; 18(5 Pt 1): 1059–62.
- 37 Price VH, Menefee E, Strauss PC. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5 % and 2 % topical minoxidil, placebo, or no treatment. J Am Acad Dermatol 1999; 41(5 Pt 1): 717–21.
- 38 Reygagne P, Assouly P, Catoni I, Jouanique C, Maffi-Berthier N, Moisson YF, Mounier P, Pfister P, Ribrioux A, Smadja J, Coudert AC, Dubertret L. Male androgenic alopecia. Randomized trial versus 2 % minoxidil. Nouv Dermatol 1997; 16(2): 59–63.
- 39 Rietschel RL, Duncan SH. Safety and efficacy of topical minoxidil in the management of androgenetic alopecia. J Am Acad Dermatol 1987; 16(3 Pt 2): 677–85.
- 40 Roberts JL. Androgenetic alopecia: treatment results with topical minoxi-dil. J Am Acad Dermatol 1987; 16(3 Pt 2): 705–10.
- 41 Roenigk HH, Pepper E, Kuruvilla S. Topical minoxidil therapy for hereditary male pattern alopecia. Cutis 1987; 39(4): 337–42.
- 42 Saraswat A, Kumar B. Minoxidil vs. finasteride in the treatment of men with androgenetic alopecia. Arch Dermatol 2003; 139(9): 1219–21.
- 43 Savin RC. Use of topical minoxidil in the treatment of male pattern baldness. J Am Acad Dermatol 1987; 16(3 Pt 2): 696–704.
- 44 Shin HS, Won CH, Lee SH, Kwon OS, Kim KH, Eun HC. Efficacy of 5 % minoxidil versus combined 5 % minoxidil and 0.01 % tretinoin for male pattern hair loss: a randomized, double-blind, comparative clinical trial. Am J Clin Dermatol 2007; 8(5): 285–90.
- 45 Shupack JL, Kassimir JJ, Thirumoorthy T, Reed ML, Jondreau L. Dose-response study of topical minoxidil in male pattern alopecia. J Am Acad Dermatol 1987; 16(3 Pt 2): 673–6.
- 46 Blume-Peytavi U, Kunte C, Krisp A, Garcia Bartels N, Ellwanger U, Hoffmann R. Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women. J Dtsch Dermatol Ges 2007; 5(5): 391–5.
- 47 DeVillez RL, Jacobs J P, Szpunar CA, Warner ML. Androgenetic alopecia in the female. Treatment with 2 % topical minoxidil solution. Arch Derma-tol 1994; 130(3): 303–7.
- 48 Jacobs JP, Szpunar CA, Warner ML. Use of topical minoxidil therapy for androgenetic alopecia in women. Int J Dermatol 1993; 32(10): 758–62.
- 49 Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, Savin RC, Tharp MD. A randomized, placebo-controlled trial of 5 % and 2 % topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol 2004; 50(4): 541–53.
- 50 Olsen EA. Topical minoxidil in the treatment of androgenetic alopecia in women. Cutis 1991; 48(3): 243–8.
- 51 Tsuboi R, Yamazaki M, Matsuda Y, Uchida K, Ueki R, Ogawa H. Antisense oligonucleotide targeting fibroblast growth factor receptor (FGFR)-1 stimulates cellular activity of hair follicles in an in vitro organ culture system. Int J Dermatol 2007; 46(3): 259–63.
- 52 Vexiau P, Chaspoux C, Boudou P, Fiet J, Jouanique C, Hardy N, Reygagne P. Effects of minoxidil 2 % vs. cypro-terone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br J Der-matol 2002; 146(6): 992–9.
- 53 Whiting DA, Jacobson C. Treatment of female androgenetic alopecia with minoxidil 2 %. Int J Dermatol 1992; 31(11): 800–4.
- 54 Tsuboi R, Tanaka T, Nishikawa T, Ueki R, Yamada H, Katsuoka K, Ogawa H, Takeda K. A randomized, placebo-controlled trial of 1 % topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. Eur J Dermatol 2007; 17(1): 37–44.
- 55 Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseu-dohermaphroditism. Science 1974; 186(4170): 1213–5.
- 56 Brenner S, Matz H. Improvement in androgenetic alopecia in 53– 76-year-old men using oral finaste-ride. Int J Dermatol 1999; 38(12): 928–30.
- 57 Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W, Price VH, Van Neste D, Roberts JL, Hordinsky M, Shapiro J, Binkowitz B, Gormley GJ. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol 1998; 39(4 Pt 1): 578–89.
- 58 Kawashima M, Hayashi N, Igarashi A, Kitahara H, Maeguchi M, Mizuno A, Murata Y, Nogita T, Toda K, Tsuboi R, Ueki R, Yamada M, Yama-zaki M, Matsuda T, Natsumeda Y, Takahashi K, Harada S. Finasteride in the treatment of Japanese men with male pattern hair loss. Eur J Dermatol 2004; 14(4): 247–54.
- 59 Khandpur S, Suman M, Reddy BS. Comparative efficacy of various treatment regimens for androgenetic alopecia in men. J Dermatol 2002; 29(8): 489–98.
- 60 Leyden J, Dunlap F, Miller B, Winters P, Lebwohl M, Hecker D, Kraus S, Baldwin H, Shalita A, Draelos Z, Markou M, Thiboutot D, Rapaport M, Kang S, Kelly T, Pariser D, Webster G, Hordinsky M, Rietschel R, Katz HI, Terranella L, Best S, Round E, Waldstreicher J. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol 1999; 40(6 Pt 1): 930–7.
- 61 Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, Wilson T, Rittmaster RS; Dutasteride Alopecia Research Team. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol 2006; 55(6): 1014–23.
- 62 Price VH, Menefee E, Sanchez M, Ruane P, Kaufman KD. Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily. J Am Acad Dermatol 2002; 46(4): 517–23.
- 63 Price VH, Menefee E, Sanchez M, Kaufman KD. Changes in hair weight in men with androgenetic alopecia after treatment with finaste-ride (1 mg daily): three- and 4-year results. J Am Acad Dermatol 2006; 55(1): 71–4.
- 64 Roberts JL, Fiedler V, Imperato-McGinley J, Whiting D, Olsen E, Shupack J, Stough D, DeVillez R, Rietschel R, Savin R, Bergfeld W, Swinehart J, Funicella T, Hordinsky M, Lowe N, Katz I, Lucky A, Drake L, Price VH, Weiss D, Whitmore E, Millikan L, Muller S, Gencheff C, Carrington P, Binkowitz B, Kotey P, He W, Bruno K, Jacobsen C, Terranella L, Gormley GJ, Kaufman KD. Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss. J Am Acad Derma-tol 1999; 41(4): 555–63.
- 65 Stough DB, Rao NA, Kaufman KD, Mitchell C. Finasteride improves male pattern hair loss in a randomized study in identical twins. Eur J Dermatol 2002; 12(1): 32–7.
- 66 Trüeb RM, Itin P. Photographic documentation of the effectiveness of 1 mg oral finasteride in treatment of androgenic alopecia in the man in routine general practice in Switzerland. Praxis 2001; 90(48): 2087–93.
- 67 Van-Neste D, Fuh V, Sanchez-Pedreno P, Lopez-Bran E, Wolff H, Whiting D, Roberts J, Kopera D, Stene JJ, Calvieri S, Tosti A, Prens E, Guar-rera M, Kanojia P, He W, Kaufman KD. Finasteride increases anagen hair in men with androgenetic alopecia. Br J Dermatol 2000; 143(4): 804–10.
- 68 Whiting DA, Waldstreicher J, Sanchez M, Kaufman KD. Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1 mg treatment of men and postme-nopausal women. J Invest Dermatol Symp Proc 1999; 4(3): 282–284.
- 69 Whiting DA, Olsen EA, Savin R, Halper L, Rodgers A, Wang L, Hustad C, Palmisano J; Male Pattern Hair Loss Study Group.Efficacy and tole-rability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. Eur J Dermatol 2003; 13(2): 150–60.
- 70 Leavitt M, Perez-Meza D, Rao NA, Barusco M, Kaufman KD, Ziering C. Effects of finasteride (1 mg) on hair transplant. Dermatol Surg 2003; 31(10): 1268–76.
- 71 Finasteride Male Pattern Hair Loss Study Group. Long-term (5-year) multinational experience with fina-steride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol 2002; 12(1): 38–49.
- 72 Brenner S, Tamir A. Treatment of and-rogenic alopecia with topical minoxi-dil. Harefuah 1991; 121(9): 297–302.
- 73 Stough D. Dutasteride improves male pattern hair loss in a randomized study in identical twins. J Cosmet Dermatol 2007; 6(1): 9–13.
- 74 Price VH, Roberts JL, Hordinsky M, Olsen EA, Savin R, Bergfeld W, Fiedler V, Lucky A, Whiting DA, Pappas F, Culbertson J, Kotey P, Meehan A, Waldstreicher J. Lack of efficacy of finasteride in postme-nopausal women with androgenetic alopecia. J Am Acad Dermatol 2000; 43(5 Pt 1): 768–76.
- 75 Diani AR, Mulholland MJ, Shull KL, Kubicek M F, Johnson GA, Schostarez HJ, Brunden MN, Buhl AE. Hair growth effects of oral administration of finasteride, a steroid 5 alpha-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque. J Clin Endocrinol Metab 1992; 74(2): 345–50.
- 76 Sovak M, Seligson AL, Kucerova R, Bienova M, Hajduch M, Bucek M. Fluridil, a rationally designed topical agent for androgenetic alopecia: first clinical experience. Dermatol Surg 2002; 28(8): 678–85.
- 77 Gassmueller J, Hoffmann R, Webster A. Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies. Br J Dermatol 2008; 158(1): 109–15.
- 78 Orfanos CE, Vogels L. Local therapy of androgenetic alopecia with 17 al-pha-estradiol. A controlled, randomized double-blind study. Dermatolo-gica 1980; 161(2): 124–32.
- 79 Wüstner H, Orfanos CE. Alopecia androgenetica and its local treatment with estrogen- and corticosteroid externa. Z Hautkr 1974; 49(20): 879–88.
- 80
Wozel G,
Narayanan S,
Jackel A,
Lutz GA.
Alfatradiol (0.025 %) – An effective and safe therapy for the treatment of androgenetic alopecia in women and men.
Aktuel Dermatol
2005; 31(12): 553–60.
10.1055/s-2005-870188 Google Scholar
- 81 Peereboom-Wynia JD, van der Willigen AH, van Joost T, Stolz E. The effect of cyproterone acetate on hair roots and hair shaft diameter in androgenetic alopecia in females. Acta Derm Venereol 1989; 69(5): 395–8.
- 82 Georgala S, Katoulis AC, Georgala C, Moussatou V, Bozi E, Stavrianeas NG. Topical estrogen therapy for androgenetic alopecia in menopausal females. Dermatology 2004; 208(2): 178–9.
- 83 Bernstein RM, Rassman WR. Dissecting microscope versus magnifying loupes with transillumination in the preparation of follicular unit grafts. A bilateral controlled study. Dermatol Surg 1998; 24(8): 875–80.
- 84 Uebel CO, da Silva JB, Cantarelli D, Martins P. The role of platelet plasma growth factors in male pattern baldness surgery. Plast Reconstr Surg 2006; 118(6): 1458–66.
- 85 Morganti P, Fabrizi G, James B, Bruno C. Effect of gelatin-cystine and serenoa repens extract on free radicals level and hair growth. J Appl Cosme-tol 1998; 16(3): 57–64.
- 86 Gehring W, Gloor M. Use of the phototrichogram to assess the stimulation of hair growth – An in vitro study of women with androgenetic alopecia. Z Hautkr 2000; 75(7–8): 419–23.
- 87 Trost LB, Bergfeld WF, Calogeras E. The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. J Am Acad Dermatol 2006; 54(5): 824–44.
- 88 Draelos ZD, Jacobson EL, Kim H, Kim M, Jacobson MK. A pilot study evaluating the efficacy of topically applied niacin derivatives for treatment of female pattern alopecia. J Cosmet Dermatol 2005; 4(4): 258–61.
- 89 Prager N, Bickett K, French N, Marcovici G. A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia. J Altern Complement Med 2002; 8(2): 143–52.
- 90 Kamimura A, Takahashi T, Watanabe Y. Investigation of topical application of procyanidin B-2 from apple to identify its potential use as a hair growing agent. Phytomedicine 2000; 7(6): 529–36.
- 91 Lassus A, Eskelinen E. A comparative study of a new food supplement, Vi-viScal, with fish extract for the treatment of hereditary androgenic alopecia in young males. J Int Med Res 1992; 20(6): 445–53.
- 92 Lassus A, Santalahti J, Sellmann M. Combined topical external and oral administration of marine polysaccharide derivatives in the treatment of hereditary androgenetic alopecia in adults. Nouv Dermatol 1994; 13(5): 254–5.
- 93 Greenberg JH, Katz M. Treatment of androgenetic alopecia with a 7.5 % herbal preparation. J Dermatol Treat 1996; 7(3): 159–62.
- 94 Kessels AG, Cardynaals RL, Borger RL, Go MJ, Lambers JC, Knottnerus JA, Knipschild PG. The effectiveness of the hair-restorer “Dabao” in males with alopecia androgenetica. A clinical experiment. J Clin Epidemiol 1991; 44(4–5): 439–47.
- 95 Otberg N, Patzelt A, Rasulev U, Hagemeister T, Linscheid M, Sinkgraven R, Sterry W, Lademann J. The role of hair follicles in the percutaneous absorption of caffeine. Br J Clin Pharmacol 2008; 65(4): 488–92.
- 96 Fischer TW, Burmeister G, Schmidt HW, Elsner P. Melatonin increases anagen hair rate in women with and-rogenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. Br J Dermatol 2004; 150(2): 341–5.
- 97 Gilhar A, Pillar T, Etzioni A. Topical cyclosporine in male pattern alopecia. J Am Acad Dermatol 1990; 22(2 Pt 1): 251–3.
- 98 Bureau JP, Ginouves P, Guilbaud J, Roux ME. Essential oils and low-intensity electromagnetic pulses in the treatment of androgen-dependent alopecia. Adv Ther 2003; 20(4): 220–9.
- 99 Maddin WS, Bell PW, James JH. The biological effects of a pulsed electrostatic field with specific reference to hair. Electrotrichogenesis. Int J Dermatol 1990; 29(6): 446–50.
- 100 Maddin WS, Amara I, Sollecito WA. Electrotrichogenesis: further evidence of efficacy and safety on extended use. Int J Dermatol 1992; 31(12): 878–80.
- 101 Policarpi F, Giorgini S, Farella V, Melli MC, Campolmi P, Panconesi E. Effects of application of a pulsed electrostatic field in male and female and-rogenic alopecia. Ann Ital Dermatol Clin Sper 1993; 47(3): 227–32.
- 102
Satino JL,
Markou M.
Hair regrowth and increased hair tensile strength using the HairMax LaserComb for low-level laser therapy.
Int J Cosmet Surg Aesthet Dermatol
2003; 5(2): 113–7.
10.1089/153082003769591209 Google Scholar
- 103 Groveman HD, Ganiats T, Klauber MR. Lack of efficacy of polysorbate 60 in the treatment of male pattern baldness. Arch Intern Med 1985; 145(8): 1454–8.
- 104 Olsen EA, DeLong E. Transdermal viprostol in the treatment of male pattern baldness. J Am Acad Derma-tol 1990; 23(3 Pt 1): 470–2.
Citing Literature
